Breakthrough T1D

Filing Period

Jul 1, 2009 to Jun 30, 2010

Signed

Feb 9, 2010

Return Version

2009v1.7

Gross Receipts

$245,877,305

Mission

Major Activities

Activity 2

4b In its goal of finding better treatments and a cure for type 1 diabetes, JDRF organizes scientific meetings, symposia, and conferences. In addition, JDRF convenes review boards consisting of scientific and lay experts to review research proposals; and provides scientific updates on the research it is managing. These activities are central to JDRF's ability to drive the agenda for type 1 diabetes research and accelerate the pace of science leading to a cure; they enable JDRF to maintain its central role as a coordinator and catalyst for diabetes science. This work also enhances JDRF's ability to forecast future scientific directions, judge the potential efficiency and effectiveness of new research pathways, and allocate its funding to where it can make the most impact in the shortest amount of time. JDRF's leadership in these areas enables it to drive diabetes research toward products and therapeutics more rapidly and effectively than it could if it were simply a funder of science.

Activity 3

4c Because of its leading role in diabetes research globally, JDRF is in a unique position to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people with the disease and their families, but also those at risk for developing the disease, and the general public. JDRF educates people about the warning signs of diabetes, which can be profoundly helpful in ensuring timely diagnoses and reducing the potential, short-term, catastrophic consequences of type 1 diabetes. JDRF also provides key information about current research directions and progress, and about human clinical trials in which people with the disease can participate (including via JDRF's Clinical Trials Connection service). JDRF chapters around the nation are committed to helping people identify and diagnose diabetes earlier and stay healthier so that they can benefit from a cure and treatments as they are developed.

Filer

EIN

23-1907729